Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Feb;197(2):391-397.
doi: 10.1016/j.juro.2016.09.113. Epub 2016 Oct 5.

Clinical Outcome of Patients with Fibrosis/Necrosis at Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Advanced Germ Cell Tumors

Affiliations

Clinical Outcome of Patients with Fibrosis/Necrosis at Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Advanced Germ Cell Tumors

Roy Mano et al. J Urol. 2017 Feb.

Abstract

Purpose: Fibrosis accounts for approximately 50% of histological findings at post-chemotherapy retroperitoneal lymph node dissection, and is associated with reported relapse rates of 10% to 15%. We characterized patients with fibrosis at post-chemotherapy retroperitoneal lymph node dissection and identified predictors of adverse outcomes in this group.

Materials and methods: We reviewed the medical records of men who underwent post-chemotherapy retroperitoneal lymph node dissection between 1989 and 2013 with histological findings of necrosis/fibrosis. With few exceptions post-chemotherapy retroperitoneal lymph node dissection after 1999 was performed with a bilateral template. Clinical, pathological and treatment related data were reported. Cox regression models were built to identify predictors of disease recurrence.

Results: The study cohort included 598 men with a median age of 32 years (IQR 25-38). Most cases (397 of 547, 73%) were classified as IGCCCG good risk, with no significant differences in risk classification before and after 1999 (p=0.55). Median followup was 7.3 years (IQR 3.2-12.3). The 5-year recurrence-free and overall survival rates were 94% and 96%, respectively. Overall 36 patients had disease recurrence, most of which was distant or outside the retroperitoneal lymph node dissection template. Procedures performed after 1999 and the presence of embryonal cell carcinoma on primary histology were associated with improved recurrence-free survival on multivariate analysis (p <0.01).

Conclusions: Disease recurrence in patients with fibrosis at post-chemotherapy retroperitoneal lymph node dissection is an uncommon yet significant event, which is less likely to occur in patients treated after 1999 and in those with embryonal carcinoma on primary histology.

Keywords: fibrosis; germ cell and embryonal; lymph node excision; neoplasms.

PubMed Disclaimer

Conflict of interest statement

and Disclosure Statement All authors have nothing to disclose.

Figures

Figure 1
Figure 1
Kaplan-Meier curves of recurrence free survival after surgery stratified by (A) the presence of embryonal carcinoma on initial histology (n=574) and (B) post-chemotherapy retroperitoneal lymph node dissection templates (n=598)

Comment in

  • Editorial Comment.
    Cary C. Cary C. J Urol. 2017 Feb;197(2):396. doi: 10.1016/j.juro.2016.09.129. Epub 2016 Nov 9. J Urol. 2017. PMID: 27836453 No abstract available.
  • Editorial Comment.
    Spiess PE, Diorio GJ. Spiess PE, et al. J Urol. 2017 Feb;197(2):396-397. doi: 10.1016/j.juro.2016.09.130. Epub 2016 Nov 9. J Urol. 2017. PMID: 27836457 No abstract available.

Similar articles

Cited by

References

    1. Stevenson SM, Lowrance WT. Epidemiology and Diagnosis of Testis Cancer. Urol Clin North Am. 2015;42:269. - PubMed
    1. Stephenson AJ, Sheinfeld J. The role of retroperitoneal lymph node dissection in the management of testicular cancer. Urol Oncol. 2004;22:225. - PubMed
    1. Donohue JP, Einhorn LH, Williams SD. Cytoreductive surgery for metastatic testis cancer: considerations of timing and extent. J Urol. 1980;123:876. - PubMed
    1. Steyerberg EW, Keizer HJ, Fossa SD, et al. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. J Clin Oncol. 1995;13:1177. - PubMed
    1. Spiess PE, Brown GA, Pisters LL, et al. Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters? Cancer. 2006;107:1503. - PubMed

MeSH terms

Substances